Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 9331003)

1.

Pharmacokinetic drug interaction studies with candesartan cilexetil.

Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Högemann A.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S31-5.

PMID:
9331003
2.

Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.

Azizi M, Chatellier G, Guyene TT, Ménard J.

J Hypertens. 1999 Apr;17(4):561-8.

PMID:
10404959
3.

Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.

Hübner R, Högemann AM, Sunzel M, Riddell JG.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S19-25.

PMID:
9331000
4.
5.

Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.

de Zeeuw D, Remuzzi G, Kirch W.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S37-42.

PMID:
9331004
6.

Candesartan cilexetil: an angiotensin II-receptor blocker.

See S, Stirling AL.

Am J Health Syst Pharm. 2000 Apr 15;57(8):739-46. Review.

PMID:
10786259
7.

Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.

Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL.

Am J Cardiol. 1999 Aug 1;84(3):289-93.

PMID:
10496437
8.
9.

Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.

Elmfeldt D, George M, Hübner R, Olofsson B.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S49-53.

PMID:
9331007
11.

Candesartan cilexetil: a review of its preclinical pharmacology.

Nishikawa K, Naka T, Chatani F, Yoshimura Y.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S9-17. Review.

PMID:
9330999
12.

Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.

Sever P.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S91-5. Review.

PMID:
9331018
13.

Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide.

Aberg JG, Olofsson B, Karlson BW.

Int J Clin Pharmacol Ther. 2011 Dec;49(12):750-5.

PMID:
22122817
14.

Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.

Jeon JY, Im YJ, Kim Y, Han SM, Jo MJ, Shin DH, Yoo JS, Moon BK, Kim BK, Lee BH, Choi YH, Cho BS, Jang HY, Chae SW, Kim MG.

Drug Dev Ind Pharm. 2013 Sep;39(9):1296-9. doi: 10.3109/03639045.2012.725732. Epub 2012 Oct 3.

PMID:
23030309
15.

Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

Pietruck F, Kiel G, Birkel M, Stahlheber-Dilg B, Philipp T.

Biopharm Drug Dispos. 2005 May;26(4):135-41.

PMID:
15768377
16.

Candesartan cilexetil: an angiotensin II receptor blocker.

Stoukides CA, McVoy HJ, Kaul AF.

Ann Pharmacother. 1999 Dec;33(12):1287-98. Review.

PMID:
10630830
17.
18.

Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.

Buter H, Navis GY, Woittiez AJ, de Zeeuw D, de Jong PE.

Eur J Clin Pharmacol. 1999 Feb;54(12):953-8.

PMID:
10192757
19.

Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

Malerczyk C, Fuchs B, Belz GG, Roll S, Butzer R, Breithaupt-Grögler K, Herrmann V, Magin SG, Högemann A, Voith B, Mutschler E.

Br J Clin Pharmacol. 1998 Jun;45(6):567-73.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk